Entrada Therapeutics Toekomstige groei
Future criteriumcontroles 0/6
Entrada Therapeutics's revenue and earnings are forecast to decline at 78.5% and 57% per annum respectively while EPS is expected to decline by 58.1% per annum.
Belangrijke informatie
-57.0%
Groei van de winst
-58.1%
Groei van de winst per aandeel
| Biotechs winstgroei | 27.1% |
| Inkomstengroei | -78.5% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 10 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding
Oct 17
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher
Aug 23Entrada Therapeutics: A Complicated Tale
Jun 16Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry
May 29These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts
Mar 19This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year
Nov 09Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)
May 26Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts
May 14Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
Mar 08We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Sep 11Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
Aug 11We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
May 28We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Jan 31Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 39 | -186 | N/A | N/A | 3 |
| 12/31/2025 | 40 | -156 | N/A | N/A | 5 |
| 12/31/2024 | 176 | 25 | N/A | N/A | 5 |
| 6/30/2024 | 239 | 104 | -18 | -14 | N/A |
| 3/31/2024 | 163 | 23 | -94 | -89 | N/A |
| 12/31/2023 | 129 | -7 | 134 | 140 | N/A |
| 9/30/2023 | 87 | -22 | 111 | 117 | N/A |
| 6/30/2023 | 43 | -82 | 109 | 114 | N/A |
| 3/31/2023 | 25 | -80 | 127 | 131 | N/A |
| 12/31/2022 | N/A | -95 | -97 | -94 | N/A |
| 9/30/2022 | N/A | -88 | -91 | -87 | N/A |
| 6/30/2022 | N/A | -78 | -77 | -74 | N/A |
| 3/31/2022 | N/A | -64 | -68 | -64 | N/A |
| 12/31/2021 | N/A | -51 | -55 | -51 | N/A |
| 9/30/2021 | N/A | -41 | -42 | -37 | N/A |
| 6/30/2021 | N/A | -34 | -33 | -29 | N/A |
| 3/31/2021 | N/A | -29 | -30 | -27 | N/A |
| 12/31/2020 | N/A | -27 | -28 | -26 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: TRDA's earnings are forecast to decline over the next 3 years (-57% per year).
Winst versus markt: TRDA's earnings are forecast to decline over the next 3 years (-57% per year).
Hoge groeiwinsten: TRDA's earnings are forecast to decline over the next 3 years.
Omzet versus markt: TRDA's revenue is expected to decline over the next 3 years (-78.5% per year).
Hoge groei-inkomsten: TRDA's revenue is forecast to decline over the next 3 years (-78.5% per year).
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if TRDA's Return on Equity is forecast to be high in 3 years time